Example data
The Polaris example project, polaris-epigenomics, comes with a cancer genomics database you can query right away. It joins three public datasets from the AWS Open Data Registry:
- TCGA (The Cancer Genome Atlas), from the NCI Genomic Data Commons, Data Release 46.0.
- Open Targets Platform, release 26.09.
- IDC (NCI Imaging Data Commons), version 25.
The data lives in one DuckDB database, epigenomics. Polaris opens it read-only.
The cohort
Section titled “The cohort”The cohort has 755 patients from two TCGA projects:
| Project | Cancer type | Patients |
|---|---|---|
| TCGA-KIRC | Kidney renal clear cell carcinoma | 363 |
| TCGA-BLCA | Bladder urothelial carcinoma | 392 |
Every patient in the cohort has clinical data and one primary tumour sample with RNA-seq expression, somatic mutations, copy number and DNA methylation. Some patients also have a matched normal tissue sample. These two projects were chosen because they have many patients with every data type, including radiology images in IDC.
Tables
Section titled “Tables”| Table | Rows | What it holds |
|---|---|---|
tcga_patients |
755 | One row per patient: clinical fields such as sex, age, stage and survival, plus imaging flags. |
tcga_samples |
1,030 | One primary tumour sample per patient, and a matched normal sample where one exists. |
tcga_files |
3,334 | The GDC open-access file behind each sample-level row. |
tcga_genes |
19,944 | Protein-coding genes (GENCODE v36). gene_id is the Ensembl id without a version. |
tcga_gene_expression |
16.7 million | STAR gene counts, one row per sample and gene. |
tcga_gene_methylation |
17.4 million | Promoter methylation beta values per sample and gene. |
tcga_gene_copy_number |
14.1 million | Gene-level copy number. 2 is normal (diploid), 0 is a homozygous deletion. |
tcga_somatic_mutations |
131,062 | Somatic mutations from whole-exome sequencing. Filter on is_nonsynonymous for protein-altering mutations. |
tcga_project_disease_map |
5 | Links each TCGA project to Open Targets disease ids. |
Open Targets
Section titled “Open Targets”| Table | Rows | What it holds |
|---|---|---|
ot_targets |
20,107 | Protein-coding drug targets, with prioritisation flags. |
ot_target_tractability |
59,587 | Tractability assessments by modality: small molecule, antibody, PROTAC and other. |
ot_associations |
32,717 | Target to disease association scores, overall and by data type. |
ot_known_drugs |
3,634 | Drugs and clinical candidates, one row per drug, disease and target. |
ot_diseases |
57 | The diseases in scope and their sub-types. |
| Table | Rows | What it holds |
|---|---|---|
idc_series |
7,910 | Metadata for imaging series: radiology (CT, MR, PET and X-ray), slide microscopy, and derived series such as segmentations. Images themselves are not included. |
Provenance
Section titled “Provenance”data_sources lists each source with its version and URL. Ask Polaris “Where does this data come from?” to see it.
How the tables join
Section titled “How the tables join”- TCGA tables join on
patient_idandsample_id. tcga_genes.gene_idjoinsot_targets.target_id, which connects mutations and expression to drug targets.tcga_project_disease_mapconnects a TCGA project to Open Targets diseases.- IDC patient ids are TCGA case barcodes, so
idc_seriesjoins the cohort by patient.
You do not need to remember any of this. The project’s RULES.md and table docs describe the joins and the common mistakes, and Polaris reads them before it writes SQL.
Optional COVID-19 data
Section titled “Optional COVID-19 data”The example project can also connect to a Snowflake database, covid19, with public COVID-19 epidemiological data (Johns Hopkins, WHO, CDC and Google mobility tables). It is a separate topic from the genomics data. If it is not connected on your deployment, Polaris tells you so.
Questions to try
Section titled “Questions to try”- How many patients in each cohort have a VHL mutation, and how many also have a PBRM1 mutation?
- Which genes are most often hypermethylated in KIRC tumours?
- Which targets associated with bladder cancer have an approved drug?
- What mix of imaging modalities does IDC have for our cohort?
- Do KIRC patients with a BAP1 mutation have shorter overall survival?